Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases

Angiogenesis

Volumn 14, Issue 3, 2011, Pages 281-291

  Liebl, Johanna ^a   Krystof, Vladimir ^b   Vereb, György ^c   Takács, Lili ^c   Strnad, Miroslav ^b   Pechan, Paul ^d   Havlicek, Libor ^b   Zatloukal, Marek ^b   Fürst, Robert ^a   Vollmar, Angelika M ^a   Zahler, Stefan ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b PALACKÝ UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d C3 Bio GmbH   (Germany)

Author keywords

Angiogenesis; Cdk; Roscovitine; Small molecule Cdk inhibitors

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; LGR 169; LGR 290; LGR 310; LGR 348; LGR 390; LGR 461; LGR 479; LGR 517; LGR 521; LGR 556; LGR 561; LGR 580; LGR 668; LGR 848; LGR 849; ROSCOVITINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL DEATH; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VASCULAR RING;

ANGIOGENESIS INHIBITORS; ANIMALS; AORTA; CELL CYCLE; CELL MOVEMENT; CELLS, CULTURED; CHICK EMBRYO; CORNEAL NEOVASCULARIZATION; CYCLIN-DEPENDENT KINASES; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; HUMANS; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; ORGAN CULTURE TECHNIQUES; PROTEIN KINASE INHIBITORS; PURINES; STEREOISOMERISM;

EID: 80052732235     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-011-9212-6     Document Type: Article

References (34)

1. AM Senderowicz 2003 Small-molecule cyclin-dependent kinase modulators Oncogene 22 6609 6620 14528286 10.1038/sj.onc.1206954 1:CAS:528: DC%2BD3sXnsl2rs7Y%3D (Pubitemid 37372341)
2. AM Senderowicz 2004 Targeting cell cycle and apoptosis for the treatment of human malignancies Curr Opin Cell Biol 16 670 678 15530779 10.1016/j.ceb.2004.09.014 1:CAS:528:DC%2BD2cXpsVOrtbY%3D (Pubitemid 39463118)
3. L Meijer A Borgne O Mulner JP Chong JJ Blow N Inagaki M Inagaki JG Delcros JP Moulinoux 1997 Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5 Eur J Biochem 243 527 536 9030781 10.1111/j.1432-1033.1997.t01-2-00527.x 1:CAS:528:DyaK2sXhtVWiu7g%3D (Pubitemid 27060443)
4. M Legraverend O Ludwig E Bisagni S Leclerc L Meijer N Giocanti R Sadri V Favaudon 1999 Synthesis and in vitro evaluation of novel 2, 6, 9-trisubstituted purines acting as cyclin-dependent kinase inhibitors Bioorg Med Chem 7 1281 1293 10465404 10.1016/S0968-0896(99)00064-4 1:CAS:528:DyaK1MXkvVGqt7c%3D (Pubitemid 29292370)
5. V Krystof R Lenobel L Havlicek M Kuzma M Strnad 2002 Synthesis and biological activity of olomoucine II Bioorg Med Chem Lett 12 3283 3286 12392733 10.1016/S0960-894X(02)00693-5 1:CAS:528:DC%2BD38XotVyrsL4%3D (Pubitemid 35251910)
6. V Krystof IW McNae MD Walkinshaw PM Fischer P Muller B Vojtesek M Orsag L Havlicek M Strnad 2005 Antiproliferative activity of olomoucine II, a novel 2, 6, 9-trisubstituted purine cyclin-dependent kinase inhibitor Cell Mol Life Sci 62 1763 1771 16003486 10.1007/s00018-005-5185-1 1:CAS:528:DC%2BD2MXhtFCgtrrP (Pubitemid 41176057)
7. IT Aldoss T Tashi AK Ganti 2009 Seliciclib in malignancies Expert Opin Investig Drugs 18 1957 1965 19938906 10.1517/13543780903418445 1:CAS:528:DC%2BD1MXhsVOhtrbO
8. T Guzi 2004 CYC-202 Cyclacel Curr Opin Investig Drugs 5 1311 1318 15648953 1:CAS:528:DC%2BD2MXmslyhug%3D%3D (Pubitemid 40074973)
9. T Tonini F Rossi PP Claudio 2003 Molecular basis of angiogenesis and cancer Oncogene 22 6549 6556 14528279 10.1038/sj.onc.1206816 1:CAS:528:DC%2BD3sXnsl2rs7o%3D (Pubitemid 37372334)
10. G Bergers D Hanahan 2008 Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 592 603 18650835 10.1038/nrc2442 1:CAS:528:DC%2BD1cXovV2lsrk%3D
11. AH Abadi SM Abou-Seri DE Abdel-Rahman C Klein O Lozach L Meijer 2006 Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents Eur J Med Chem 41 296 305 16494969 10.1016/j.ejmech.2005.12.004 1:CAS:528:DC%2BD28XjslChtb4%3D
12. L Maggiorella C Aubel C Haton F Milliat E Connault P Opolon E Deutsch J Bourhis 2009 Cooperative effect of roscovitine and irradiation targets angiogenesis and induces vascular destabilization in human breast carcinoma Cell Prolif 42 38 48 19143762 10.1111/j.1365-2184.2008.00570.x 1:CAS:528: DC%2BD1MXislCmt7k%3D
13. Zahler S, Liebl J, Furst R, Vollmar AM (2010) Anti-angiogenic potential of small molecular inhibitors of cyclin dependent kinases in vitro. Angiogenesis
14. Liebl J, Weitensteiner SB, Vereb G, Takacs L, Füerst R, Vollmar AM, Zahler S (2010) Cyclin dependent kinase 5 (Cdk5) regulates endothelial cell migration and angiogenesis. J Biol Chem
15. L Havlicek J Hanus J Vesely S Leclerc L Meijer G Shaw M Strnad 1997 Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds J Med Chem 40 408 412 9046330 10.1021/jm960666x 1:CAS:528:DyaK2sXhsVSrsbs%3D (Pubitemid 27080019)
16. M Otyepka V Krystof L Havlicek V Siglerova M Strnad J Koca 2000 Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2 J Med Chem 43 2506 2513 10891109 10.1021/jm990506w 1:CAS:528: DC%2BD3cXjs1Ogsr0%3D (Pubitemid 30437132)
17. NS Gray L Wodicka AM Thunnissen TC Norman S Kwon FH Espinoza DO Morgan G Barnes S LeClerc L Meijer, et al. 1998 Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors Science 281 533 538 9677190 10.1126/science.281.5376.533 1:CAS:528:DyaK1cXkvFCltr8%3D (Pubitemid 28357362)
18. AK Kiemer NC Weber R Fürst N Bildner S Kulhanek-Heinze AM Vollmar 2002 Inhibition of p38 MAPK activation via induction of MKP-1: atrial natriuretic peptide reduces TNF-alpha-induced actin polymerization and endothelial permeability Circ Res 90 874 881 11988488 10.1161/01.RES.0000017068. 58856.F3 1:CAS:528:DC%2BD38XjslWntbc%3D (Pubitemid 34633879)
19. A Koltermann J Liebl R Fürst H Ammer AM Vollmar S Zahler 2009 Ginkgo biloba extract EGb 761 exerts anti-angiogenic effects via activation of tyrosine phosphatases J Cell Mol Med 13 2122 2130 19175691 10.1111/j.1582-4934. 2008.00561.x
20. I Nicoletti G Migliorati MC Pagliacci F Grignani C Riccardi 1991 A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry J Immunol Methods 139 271 279 1710634 10.1016/0022-1759(91) 90198-O 1:CAS:528:DyaK3MXltlenu7Y%3D
21. BM Kenyon EE Voest CC Chen E Flynn J Folkman RJ D'Amato 1996 A model of angiogenesis in the mouse cornea Invest Ophthalmol Vis Sci 37 1625 1632 8675406 1:STN:280:DyaK283psFersg%3D%3D (Pubitemid 26271414)
22. T Licht L Tsirulnikov H Reuveni T Yarnitzky SA Ben-Sasson 2003 Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 (EDG3) Blood 102 2099 2107 12763936 10.1182/blood-2002-12-3634 1:CAS:528:DC%2BD3sXntlKrsrg%3D (Pubitemid 37122386)
23. WF De Azevedo S Leclerc L Meijer L Havlicek M Strnad SH Kim 1997 Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine Eur J Biochem 243 518 526 9030780 10.1111/j.1432-1033.1997.0518a.x (Pubitemid 27060442)
24. S Bach M Knockaert J Reinhardt O Lozach S Schmitt B Baratte M Koken SP Coburn L Tang T Jiang, et al. 2005 Roscovitine targets, protein kinases and pyridoxal kinase J Biol Chem 280 31208 31219 15975926 10.1074/jbc.M500806200 1:CAS:528:DC%2BD2MXpsVCmurY%3D (Pubitemid 41291858)
25. B Menn S Bach TL Blevins M Campbell L Meijer S Timsit 2010 Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models PLoS One 5 e12117 20711428 10.1371/journal.pone.0012117
26. G Feldmann A Mishra SM Hong S Bisht CJ Strock DW Ball M Goggins A Maitra BD Nelkin 2010 Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling Cancer Res 70 4460 4469 20484029 10.1158/0008-5472.CAN-09-1107 1:CAS:528:DC%2BC3cXmslWgt78%3D
27. CJ Strock JI Park EK Nakakura GS Bova JT Isaacs DW Ball BD Nelkin 2006 Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells Cancer Res 66 7509 7515 16885348 10.1158/0008-5472.CAN-05-3048 1:CAS:528:DC%2BD28XnsFyrtbg%3D (Pubitemid 44289205)
28. Liu JL, Wang XY, Huang BX, Zhu F, Zhang RG, Wu G (2010) Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis. Med Oncol
29. J Liu DL Zhang SG Shan 2008 Expression and clinical significance of cyclin H and CDK7 in human hemangiomas Zhonghua Zheng Xing Wai Ke Za Zhi 24 300 302 18950027
30. N Wagner C Jehl-Pietri P Lopez J Murdaca C Giordano C Schwartz P Gounon SN Hatem P Grimaldi KD Wagner 2009 Peroxisome proliferator-activated receptor beta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin Cardiovasc Res 83 61 71 19351742 10.1093/cvr/cvp106 1:CAS:528:DC%2BD1MXntlGhtLg%3D
31. S Ali DA Heathcote SH Kroll AS Jogalekar B Scheiper H Patel J Brackow A Siwicka MJ Fuchter M Periyasamy, et al. 2009 The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity Cancer Res 69 6208 6215 19638587 10.1158/0008-5472.CAN-09-0301 1:CAS:528:DC%2BD1MXpt1Cgtbs%3D
32. RP Fisher 2005 Secrets of a double agent: CDK7 in cell-cycle control and transcription J Cell Sci 118 5171 5180 16280550 10.1242/jcs.02718 1:CAS:528:DC%2BD2MXhtlWru73F (Pubitemid 41819581)
33. J Pirngruber A Shchebet SA Johnsen 2009 Insights into the function of the human P-TEFb component CDK9 in the regulation of chromatin modifications and co-transcriptional mRNA processing Cell Cycle 8 3636 3642 19844166 10.4161/cc.8.22.9890 1:CAS:528:DC%2BC3cXotlWrs7c%3D
34. V Krystof S Uldrijan 2010 Cyclin-dependent kinase inhibitors as anticancer drugs Curr Drug Targets 11 291 302 20210754 10.2174/ 138945010790711950 1:CAS:528:DC%2BC3cXkt1emsr0%3D